National Cancer Institute NCI Cancer Bulletin: A Trusted Source for Cancer Research News
March 10, 2009 • Volume 6 / Number 5

The information and links on this page are no longer being updated and are provided for reference purposes only.

Notes

New NCI Fellowship Honors Dr. Alan Rabson

Dr. Alan Rabson Dr. Alan Rabson

The U.S. House Appropriations Committee has directed NCI to establish a fellowship honoring Dr. Alan S. Rabson, deputy director of NCI, in recognition of his 53 years of service to NIH. The directive to establish the “Alan S. Rabson Award” was part of the explanatory statement accompanying the FY2009 Omnibus Appropriations Act (H.R. 1105) passed by the U.S. House of Representatives on February 25. The statement acknowledges Dr. Rabson’s work as a pathologist, researcher, administrator, and clinical advisor, and highlights his numerous discoveries in virology and authorship of more than 100 scientific journal articles. In particular, the statement recognizes Dr. Rabson’s life-long dedication to helping cancer patients and their families cope with their diagnoses. The statement also honors the service of Dr. Rabson’s wife, Dr. Ruth L. Kirschstein, who served as the acting director of NIH and director of several institutes. NCI plans to implement this directive in the near future.

NCI Lecture Series Features Dr. Michael Jung

Dr. Michael Jung Dr. Michael Jung

NCI’s Center for Cancer Research (CCR) continues its “Eminent Lecture Series,” with presentations by nationally recognized scientists working on cutting-edge research designed to stimulate a scientific exchange of ideas. 

Dr. Michael Jung, professor in the Department of Chemistry and Biochemistry at the University of California, Los Angeles, will present the next lecture on March 23 at 3:00 p.m. in Lipsett Amphitheater on the NIH campus in Bethesda. The title of Dr. Jung’s talk is “Rational Drug Design for the Treatment of Hormone Refractory Prostate Cancer.” Dr. Jung is an authority on synthetic organic and medicinal chemistry and has more than 25 patents. His lab developed an antagonist of the androgen receptor, which is in phase I and II clinical trials for the treatment of hormone refractory prostate cancer. The lecture series is free and open to the public.

Call for U.S.-Japan Workshop Proposals

NCI and the Japan Society for the Promotion of Science (JSPS) are soliciting proposals for a workshop supporting advances in cancer research and clinical care. The workshop is held annually in the U.S. or Japan, and its theme alternates between basic, clinical, and epidemiological and behavioral science. Proposals are now being accepted for the 2009–2010 workshop, which will focus on epidemiology and behavioral sciences. Participation is limited to 20 people each from the U.S. and Japan, with the possibility for a small number of third country participants. The submission deadline is April 30, and the selection process should be completed by July 2009. More information and proposal submission forms are available from NCI’s Office of International Affairs.

BSA Meeting Held

NCI’s Board of Scientific Advisors (BSA) met March 2–3 on the NIH campus in Bethesda, MD. The public portions of the meeting can be viewed at http://videocast.nih.gov/PastEvents.asp.

First Lady of Senegal Visits NCI

First Lady of Senegal, Viviane Wade, and Dr. Joe Harford First Lady of Senegal, Viviane Wade, and Dr. Joe Harford

The First Lady of Senegal, Mrs. Viviane Wade, visited NCI on January 16. Since the election of her husband, President Abdoulaye Wade, in 2002, Mrs. Wade has dedicated herself to the health and well-being of the people of Senegal. She is the president of Association Education Santé, a nongovernmental agency focusing on the needs of impoverished communities, especially those of children, in remote areas of Senegal. Mrs. Wade has also organized and participated in symposia in Africa on economic empowerment and education for women, public health issues (e.g., HIV/AIDS, malaria, malnutrition, and sickle cell anemia), and agriculture.

During her visit, Mrs. Wade toured the NIH Clinical Center, led by Dr. Lee Helman of NCI’s Center for Cancer Research, and heard presentations by representatives from NIH’s Fogarty International Center (FIC) and various NCI staff. These presentations focused on the burden of cancer in Africa, an overview of FIC and NCI, cancer control planning and screening, and affordable cervical cancer screening in Senegal. Speakers included Dr. James Herrington, director of FIC’s Division of International Relations; Dr. Joe Harford, director of NCI’s Office of International Affairs (OIA); Dr. Makeda Williams of OIA; Dr. Deidre Lawrence, Cynthia Vinson, and Dr. Stephen Taplin of NCI’s Division of Cancer Control and Population Sciences; and Dr. Mark Schiffman of NCI’s Division of Cancer Epidemiology and Genetics. Potential collaborations with NCI on cancer screening and prevention in Senegal were discussed, as Mrs. Wade’s priorities include improving clinical care, education, and health outcomes in Senegal.

New Orleans Community Clinical Programs Honored

The NCI’s Community Clinical Oncology Program honored its two Louisiana CCOPs with the Harry Hynes Award for excellence in community clinical research on March 2. The Oschner Community Clinical Oncology Program and the Minority-based CCOP at Louisiana State University’s Stanley S. Scott Cancer Center (SSSCC) were recognized for their efforts after Hurricane Katrina on behalf of patients with cancer and for their cancer prevention and control efforts. Dr. Carl G. Kardinal, the retired principal investigator of the Oschner CCOP, and Drs. Augusto Ochoa and John Estrada from SSSCC were also included in the awards.

The CCOP program established the Harry Hynes Award in 2001 to recognize and acknowledge outstanding commitment by community investigators to clinical research. The award was named for Dr. Harry Hynes, the principal investigator of the Wichita Community Clinical Oncology Program, for his tremendous dedication and commitment to bringing clinical trials to the community setting.